Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 17/20 | 0.47 |
| ▸ | ACACA | Q13085 | 16/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391871 | 1.00 | ACACB (0.47) | ACACBACACASMN1; SMN2NPC1HPGD | |
| SCHEMBL4391864 | 1.00 | ACACB (0.47) | ACACBACACASMN1; SMN2NPC1HPGD | |
| SCHEMBL4390164 | 0.92 | ACACB (0.47) | ACACBACACASMN1; SMN2NPC1HPGD | |
| SCHEMBL4390170 | 0.92 | ACACB (0.47) | ACACBACACASMN1; SMN2NPC1HPGD | |
| SCHEMBL4390157 | 0.92 | ACACB (0.47) | ACACBACACASMN1; SMN2NPC1HPGD | |
| SCHEMBL4391617 | 0.92 | ACACB (0.47) | ACACBACACASMN1; SMN2NPC1HPGD | |
| SCHEMBL4391612 | 0.92 | ACACB (0.47) | ACACBACACASMN1; SMN2NPC1HPGD | |
| SCHEMBL4390051 | 0.91 | ACACB (0.51) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4390044 | 0.91 | ACACB (0.51) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4390055 | 0.91 | ACACB (0.51) | ACACBACACACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885SMN1; SMN2 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.